Skip to content

The value of PSMA PET/CT on evaluating the efficacy of neoadjuvant chemotherapy in prostate cancer

The value of PSMA PET/CT on evaluating the efficacy of neoadjuvant chemotherapy in prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047630
Enrollment
Unknown
Registered
2021-06-21
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with clinical diagnosis of prostate cancer; 2. Patients who underwent PSMA PET/CT examination before chemotherapy and underwent PSMA PET/CT examination again before surgery after chemotherapy; 3. Complete clinical pathological data.

Exclusion criteria

Exclusion criteria: 1. Patients who have received other adjuvant chemotherapy, radiotherapy, immunotherapy and other adjuvant therapy before chemotherapy; 2. Have a history of severe allergy to related chemotherapeutic drugs and imaging agents; 3. Patients with acute urinary tract infection; 4. Severe organ dysfunction, such as heart, lung, liver, and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Maximal standard uptake value;Mean standard uptake value;Peak standard uptake value;Positive distribution area of lesions;Enhancement rate;Age;Body Mass Index;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactXu Ning
drxun@fjmu.edu.cn+86 13235907575

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026